Novocure announced that Mr. Asaf Danziger, who has served as CEO since 2002, will serve as Senior Advisor into early 2026, and will continue to serve on Novocure?s Board of Directors. These changes will become effective on January 1, 2025. that Wilco Groenhuysen will step down as Chief Operating Officer (COO) effective October 1, 2024.
Mukund Paravasthu, who joined Novocure in 2020 and currently holds the position of Senior Vice President, Product Development, will expand his current responsibilities and transition into the role of COO. Asaf Danziger has served as Novocure?s Chief Executive Officer since 2002 and has been a member of the Board of Directors since 2012. Mr. Danziger was Novocure?s fourth employee, leading the organization from its preclinical development stage through regulatory approvals and product commercialization, growing Novocure into an organization with over $500 million in annual global sales and more than 1,500 employees.
Mr. Danziger holds a Bachelor of Science in material engineering from Ben-Gurion University of the Negev, Israel.
